U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820268) titled 'A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies' on Jan. 09.
Brief Summary: Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
Study Start Date: Jan. 14
Study Type: INTERVENTIONAL
Condition:
B-cell Lymphoma
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Intervention:
OTHER: XS-04 tablet
Each treatment cycle is 28 days, with continuous oral administration, twice daily.
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: NovaOnco Therapeutics Co., Ltd.
Published by HT Digital Content S...